title: Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases.
abstract: BACKGROUND
  Docetaxel (Taxotere) is a microtubule-stabilizing agent that is potentially important in chemotherapy for a variety of malignancies.
  
  
  METHODS
  A clinical study of the cutaneous reactions experienced by a group of patients receiving docetaxel chemotherapy was undertaken. Patients were examined before initiation of therapy, before and after each cycle of therapy, and were followed subsequent to the completion of docetaxel chemotherapy.
  
  
  RESULTS
  Three patients developed diffuse lower extremity edema (3-18 kg) and subsequent scleroderma-like changes after receiving multiple cycles of docetaxel therapy. These patients had different underlying malignancies and dissimilar prior therapy. Rheumatoid factor, antinuclear antibodies, anticentromere, and topoisomerase antibodies were not present in any patient. The diffuse lower extremity edema did not resolve with diuretic therapy. Cutaneous biopsies in two patients revealed diffuse sclerosis. One patient had a normal lymphangiogram during the edematous phase. Discontinuation of docetaxel correlated with resolution of edema and softening of the skin.
  
  
  CONCLUSIONS
  The etiology of the scleroderma-like skin changes is unclear but appears to be either a toxic effect of docetaxel or an effect of polysorbate 80 (Tween 80), the vehicle for docetaxel.
authors.affiliation: Department of Medicine, Brooke Army Medical Center, San Antonio, Texas 78234, USA.
authors.forename: D F
authors.initials: DF
authors.lastname: Battafarano
authors.forename: G C
authors.initials: GC
authors.lastname: Zimmerman
authors.forename: S A
authors.initials: SA
authors.lastname: Older
authors.forename: J H
authors.initials: JH
authors.lastname: Keeling
authors.forename: H A
authors.initials: HA
authors.lastname: Burris
mesh_terms: D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects*; D000077143:Docetaxel; D004487:Edema / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007866:Leg / Q000473:pathology*; D007890:Leiomyosarcoma / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects / Q000031:analogs & derivatives*; D012594:Scleroderma, Localized / Q000139:chemically induced* / Q000473:pathology; D043823:Taxoids
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel